摘要
目的:研究急性ST段抬高心肌梗死(ASTEMI)静脉溶栓药物的疗效及副反应的比较。方法:随机分组选用114例ASTEMI用重组链激酶(r-sk)及124例ASTEMI用尿激酶(UK)分别做全身静脉溶栓,比较疗效及副反应。结果:r-sk与UK在治疗ASTEMI的再通率分别为81.6%、69.3%,两组比较有显著差异(P<0.05)。副反应亦有显著差异(P<0.05)结论:应用r-sk血管再通率高,是治疗ASTEMI有效安全的溶栓药物。
Objective：To compare the efficacy and side effects of different intravenous thrombolytic medicines in acute myocardial infarction patients with ST segment elevation （ASTEMI）. Methods： Recombinant streptokinase（r-SK） was used in the intravenous thrombolysis treatment of 114 randomly chosen ASTEMI patients while urokinase（UK） was used in another group of 124 randomly chosen ASTEMI patients. The therapeutic efficacy and side effects were compared in these two groups. Results：The reperfusion rates were 81.6%and 69.3%, respectively, in the treatment of ASTEMI with r-SK and UK. There is a significant difference between these two groups （P〈0.05）. There is a significant difference（P〈0.05） in side effects between these two groups as well. Conclusion：The vascular recanalization rate is high with r-SK. It＆#39;s safe and effective in the thrombolytic therapy of ASTEMI patients.
出处
《中国医药导刊》
2014年第3期480-481,共2页
Chinese Journal of Medicinal Guide
关键词
急性ST段抬高心肌梗死
溶栓药物
疗效比较
Acute myocardial infarction with ST segment elevation
Thrombolytic medicine
Efficacy comparison
